News and Announcements
Aviator Capital is pleased to announce the launch of the Harbourview Fund in Darwin
- Published August 11, 2022 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Harbour View Plaza is a landmark Darwin City office building that has a strong track record of occupancy accommodating a mixture of NT Government and Federal Government tenants. NT Government lease expiry is out to 2033. The building is currently 100% leased. Significant capital expenditure upgrading the property and its facilities has further enhanced the quality of the asset and provides Aviator’s investors with a lower risk secure long-term investment.
Darwin is central to the Northern Territory’s diversified economy, which is expected to grow by 53%, in terms of Gross State Product (GSP), by 2030. The Territory is experiencing significant investment totalling approximately $29.9Bin current projects.
(Northern Territory Government, 2022)
The key investment highlights of the property at 8 McMinn Street Darwin are:
| Site Area | 5,330 m2 |
| Gross Lettable Area | 5,775.4 m2 over 6 levels |
| Car Parking | 155 undercover and on-grade car parks |
| Sustainability (NABERS) | 5.5 Star |
| Fully Leased Gross Income | $2,471,065 (Estimated) |
| Estimated Outgoings | $501,728 |
| Fully Leased Net Income | $1,969,337 (Estimated) |
| WALE | 7.7 years (by area) at 30 June 2022 |
| CAPEX | $5.9m spent on major works |
This is an exciting opportunity in invest in the Darwin CBD with distributions from the Fund commencing at 8.5% per annum paid monthly.
Aviator Capital looks forward to welcoming you as an investor in the Aviator Harbourview Fund.
Company Updates
From Algae Pioneers to a Natural Revolution: The Second Act of WRS Bioproducts
As the US FDA prepares to phase out synthetic food colors by the end of 2026, WRS Bioproducts is stepping in to solve a looming supply crisis. Led by industry pioneer Harry Rosen, the company is leveraging 40 years of industrial algae farming expertise to scale production of natural, superior-quality beta-carotene, positioning itself as a vital supplier in the rapidly shifting global market for natural ingredients.
Dying for a Cure: Why Astraea is Stress-Testing the Future of Space Medicine
Astraea Technologies is solving a critical “blind spot” in the $1.5T space economy. Co-founders Brooke Mills and Gordon Carroll discuss their $5M seed raise, the HIRO-LAB platform, and their upcoming 2028 mission to the Moon to validate life-saving medicine in extreme environments.
Beyond the Drip: Elemental IV’s Infrastructure Play for a Fragile Supply Chain
In the high-stakes world of life sciences, we often hunt for the next “miracle molecule” or gene-editing breakthrough. But Storme Paes, Founder and Commercial Director of Elemental IV, found her mission in something far more fundamental, yet dangerously overlooked: a simple bag of saltwater. The “Meeting Room” Revelation The genesis of Elemental IV didn’t occur […]
Backed By Leading Investment Groups and Family Offices
